Gene therapy revolution – Bluebird Bio raises 250 million dollars

Recently Cambridge-based Bluebird Bio has raised 250 million dollars in a new

stock offering. Biotech had priced an offering of 3.3 million shares at 76 dollars

per share with an additional 493420 shares available to underwriters. The offering

comes after Bluebird presented initial clinical data from an early stage trial. The

data showed that seven out of nine patients has responded favorably and

boosting the company’s share price to new stature. Sachs & co., Goldman, and

Cowen are acting as joint book-running managers for offering. Wells Fargo

securities and Wedbush pac grow are acting as co-managers. The Bluebird bio

foresees the total proceeds from the offering will be roughly 250 million dollars.

Shares have been offered by Bluebird Bio pursuant to an automatically effective

self-registration statement.

Bluebird bio has built an integrated product podium with wide potential

applications to severe genetic diseases and cancer. Bluebird’s gene therapy

clinical, programs the company’s main objective to build up and bring to market

the most advanced products. Based on the transformative potentials of gene

therapy it offers patients the hope for a better life in face of no long term effective

and safe options. The company has its headquarters in Cambridge,

Massachusetts and has its operations in US and Europe.

Source: www.bluebirdbio.com

Gene therapy revolution – Bluebird Bio raises 250 million dollars
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

To Top